Teduglutide vs ARA-290
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
TeduglutideImmune SupportRecovery & Repair
ARA-290- Summary
- Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Half-Life
- ~2 hours; once-daily dosing due to gut-specific residence
- ~2–4 hours (SC administration)
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.05 mg/kg/day
- 4 mg (fixed dose)
- Frequency
- Once daily
- Once daily
- Key Benefits
- Increases intestinal villus height and absorption surface area
- Reduces intestinal permeability (leaky gut)
- FDA-approved for short bowel syndrome
- Reduces parenteral nutrition dependence in SBS patients
- Promotes intestinal mucosal healing in IBD
- Increases tight junction proteins ZO-1 and occludin
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Side Effects
- Injection site reactions
- Abdominal pain and bloating
- Nausea
- Risk of intestinal polyp growth (requires colonoscopy surveillance)
- +1 more
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Stacks With
- —
- —